Ipilimumab: Preliminary Phase II data

Top-line data from the double-blind Phase II 022 trial showed that ipilimumab had dose-dependent effects. Patients received 0.3, 3 or 10 mg/kg of ilipimumab monotherapy. Additional data were not discl...